Arcus Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the Annual Meeting of Stockholders held by Arcus Biosciences, Inc. on June 11, 2026. The filing was submitted on June 12, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Class II Directors): All four nominees were elected.
- Dietmar Berger, M.D., Ph.D.: 85,949,508 votes for; 18,338,022 withheld.
- David Lacey, M.D.: 85,974,583 votes for; 18,312,947 withheld.
- Nicole Lambert: 92,653,341 votes for; 11,634,189 withheld.
- Johanna Mercier: 85,941,754 votes for; 18,345,776 withheld.
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Votes For: 112,905,582
- Votes Against: 4,767,430
- Abstentions: 187,745
- Proposal 3 (Advisory Executive Compensation): The compensation of named executive officers was approved on an advisory basis.
- Votes For: 94,920,421
- Votes Against: 9,337,368
- Abstentions: 29,741
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Confirm the tenure of the newly elected Class II directors, which extends until the 2029 Annual Meeting.
- Review the full Proxy Statement for detailed executive compensation data referenced in Proposal 3.
- Note the significant number of broker non-votes (13,573,227) recorded for the director election and executive compensation proposals.